Navigation Links
DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial
Date:7/24/2014

cer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI) and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action. DelMar's scientific presentations can be viewed on the company's website at www.delmarpharma.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.


'/>"/>
SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting
2. DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
3. DelMar Pharmaceuticals Gives Quarterly Shareholder Update
4. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
5. DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
6. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
7. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
8. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
10. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015 BioCorRx, ... Santa Ana, California is a healthcare ... for which is estimated at $22 billion in the U.S. ... the use of FDA-approved Naltrexone in a specially compounded form ... Australia and New Zealand ...
(Date:3/27/2015)... March 27, 2015 Across the global healthcare ... challenges in clinical development, market education, and regulatory compliance. ... Medical Affairs function is expected to increase in prominence ... According to research by benchmarking firm, Best ... group dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... 2015  The quality function within the medical device ... quality standards at every stage of the product life ... also have the challenge of balancing quality and safety ... don,t effectively balance these priorities risk funding and staffing ... and regulatory scrutiny. For the third consecutive ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2
... Clinical trials in which participants are randomly assigned to different ... conducted correctly, it,s widely accepted by the research community that ... But researchers at the University of Michigan hope to ... patients by investigating the impact of a class of innovative ...
... CRY ), an implantable biological medical device ... BioGlue Surgical Adhesive has received Shonin approval from the ... use in the repair of aortic dissections. ... in Japan for use in this subset of cardiac ...
Cached Medicine Technology:U-M Receives NIH, FDA Grant To Study Adaptive Clinical Trial Design 2CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 2CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 3CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 4CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 5
(Date:3/28/2015)... AZ (PRWEB) March 28, 2015 Coffee could ... also help protect you from gum disease, researchers have found. ... against gum disease. , Coffee contains antioxidants. Antioxidants fight gum ... the question researchers at Boston Univ. Henry M. Goldman School ... in the August 2014 issue of the Journal of Periodontology. ...
(Date:3/28/2015)... March 28, 2015 Could genetic code ... new study by researchers at the Harvard ... with the support of the Coffee and Caffeine Genetics ... Psychiatry this past fall, the study—one of several recent ... genomic data from more than 120,000 regular coffee drinkers ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part ... the latest and coolest applications on the market for ... NewsWatch and technology expert, conducted the app review and ... runner game with knights, nature, and peasants. , ... according to Eurogamer. The popularity of these games grew ...
(Date:3/28/2015)... Take a bite of warm, gooey pepperoni ... tumble into the stomach, ready to break down your ... these acids run amok, triggering a burning sensation in ... than 60 million Americans have heartburn at least once ... and how it can be stopped. , Heartburn or ...
(Date:3/28/2015)... 28, 2015 With more than ... fields of osteoporosis, osteoarthritis and musculoskeletal diseases gathered ... may be the first time in the 17-year ... that the hot-button topic is an emerging non-pharmaceutical ... well-accepted scientific principles of Wolff’s law, osteogenic loading ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2
... BeneChill, Inc. ( www.benechill.com ) today announced the ... study. This randomized study will determine whether intra-nasal ... patient resuscitation and survival rates.The PRINCE study is ... Europe. The company received CE marking for the ...
... manufacturer of,GUM(R) and Butler(R) brand products and a leader ... worldwide, is putting its support,behind the American Dental Association,s ... health. , Each February since ... to raise awareness about the importance of oral health. ...
... most symptoms fade within 6 weeks, experts say , , ... physical therapy and anti-inflammatory drugs is the most effective ... degenerative disc disease, according to a review of published ... 90 percent of people with low back pain, symptoms ...
... part in regular physical activity have a better quality ... issue of the journal Cancer Epidemiology Biomarkers and ... more physically active report better mood, more vigor, and ... take-home message is that early-stage lung cancer survivors may ...
... ANN ARBOR, Mich. One-fifth of women who should ... potentially lifesaving treatment, according to a new study from ... , The study looked at 396 women who were ... found that 19 percent of women who fell clearly ...
... Vitamin(R) has launched the web site for Keep ,Em ... that gives pregnant women the greatest opportunity to carry ... information and offering online community support. , ... Cookin, with one very specific goal in mind --- ...
Cached Medicine News:Health News:BeneChill Launches European Study of Intra-Arrest Cooling 2Health News:Sunstar to Support ADA's 60th Annual National Children's Dental Health Month 2Health News:Sunstar to Support ADA's 60th Annual National Children's Dental Health Month 3Health News:Therapy, Meds Best for Lumbar Low Back Pain 2Health News:Regular physical activity linked to better quality of life in early-stage lung cancer survivors 2Health News:19 percent of breast cancer patients don’t receive recommended radiation after mastectomy 2Health News:Vitamin Launches Online Face for Keep 'Em Cookin' 2
Benchtop UV Incubator is designed to provide precise temperature control and uniformity throughout the chamber. Decontaminate chamber between experiments with built-in shortwave UV....
Inquire...
Inquire...
Inquire...
Medicine Products: